+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Global Non-Small Cell Lung Cancer Therapeutics Market to Reach US$15.1 bn by 2023, Asia Pacific to Report Fastest CAGR

Posted on Apr 08, 2016

A research study, recently published by Transparency Market Research (TMR), estimates the global non-small cell lung cancer (NSCLC) therapeutics market to expand at a healthy CAGR of 12.10% over the period from 2015 to 2023 and reach a value of US$15.1 bn by the end of the forecast period.The report, titled “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023,” states that the worldwide NSCLC market attained US$4.9 bn in 2014.

Browse the full Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023 report at http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

Non-small cell lung cancer (NSCLC) has been identified as the most common type of epithelial lung cancer. Adenocarcinomas, squamous cell carcinomas, and large cell carcinomas are the major types of NSCLC. Unlike small cell lung cancer (SCLC), NSCLC exhibits low receptivity to chemotherapy, owing to which, the need for NSCLC therapeutics has been persistently escalating in the global arena.

In this research report, the global market for NSCLC therapeutics has been evaluated on the basis of the drug class, the pipeline stage, and the regional spread of this market. Based on the drug class, the market has been classified into angiogenesis inhibitor, kinase inhibitor, epidermal growth factor receptor blocker, microtubule stabilizer, PD-1/PD-L1 Inhibitor, and folate antimetabolites.

In 2014, angiogenesis inhibitor was the most demanded drug class in the global arena. The high efficiency of this drug class fueled its demand in the U.S., Japan, Europe, and other major regions.

Avastin and Cyramza are the two main angiogenesis inhibitors available in this market. Analysts expect this segment to expand at a CAGR of 1.80% during the forecast period and increase from a value of US$1.6 bn in 2014 to US$2 bn by the end of the forecast period.

Based on the pipeline stage, NSCLC therapeutics has been categorized into early-stage (phase 1 and phase 2) pipeline drugs and late-stage (phase 3) pipeline drugs. MEDI4736 (AstraZeneca), Avelumab (Pfizer Inc.), Abemaciclib (Eli Lilly and Co.), and MPDL3280A (Roche) are the major late-stage pipeline drugs.

Regionally, the study segments the global market for NSCLC therapeutics into Asia Pacific, Europe, North America, and the Rest of the World. North America led the overall market in 2014 and was closely followed by Asia Pacific. However, Asia Pacific is anticipated to register the fastest growth rate over the forecast period.

The presence of state-of-art healthcare infrastructure and existence of a favorable reimbursement scenario are the key factors that drove the North America NSCLC therapeutics market. Besides, the growing awareness about NSCLC and the increasing implementation of government initiative to curb lung cancer are likely to boost the Asia Pacific market for NSCLC therapeutics in the coming years, notes the study.

AstraZeneca Plc, GlaxoSmithKline Plc, Genentech Inc., Eli Lilly & Co., Boehringer Ingelheim, Pfizer Inc., Celgene Corp., Roche Holding AG, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the leading players in the global NSCLC therapeutics market, states the research report.

The global NSCLC market is segmented into:

By Drug Class

  • Angiogenesis Inhibitor
    • Avastin (bevacizumab)
    • Cyramza (Ramucirumab)
  • Epidermal Growth Factor Receptor Blocker
    • Tarceva (erlotinib)
    • Gilotrif (afatinib)
    • Iressa (gefitinib)
  • Kinase Inhibitor
    • Xalkori (crizotinib)
    • Zykadia (ceritinib)
  • Microtubule Stabilizer
    • Abraxane (paclitaxel protein bound)
    • Docetaxel
  • Folate Antimetabolites
    • Alimta (pemetrexed)
  • PD-1/ PD-L1 Inhibitor
    • Opdivo (nivolumab)
    • Keytruda (pembrolizumab)

By Pipeline

  • Early-Stage (Phase I and II)
  • Late-Stage (Phase III)
    • Avelumab Pfizer Inc.)
    • MPDL3280A (Roche)
    • MEDI4736 (AstraZeneca)
    • Abemaciclib (Eli Lilly and Co.)
    • Others

 

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of the World

 

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

 

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Back To Top